Clinical trial

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

NCT01706926

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Mavrilimumab 30 mg Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Mavrilimumab 100 mg Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Mavrilimumab 150 mg Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-08-01

PhasePHASE2

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

Mavrilimumab 30 mgBIOLOGICAL

Mavrilimumab 100 mgBIOLOGICAL

Mavrilimumab 150 mgBIOLOGICAL

PlaceboOTHER

Sponsors & collaborators

MedImmune LLClead sponsor

MedImmune Ltdcollaborator

Mapped research locations

BarcelonaSpain1 MoscowRussia1 WarsawPoland1 BudapestHungary1 Saint PetersburgRussia1 PragueCzechia1 KrakowPoland1 SofiaBulgaria1 WroclawPoland1 CologneGermany1 KharkivUkraine1 BelgradeSerbia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01706926 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.